Doppalapudi Sai Krishnaraya, Leopold Zev R, Thaper Akshay, Kaldany Alain, Chua Kevin, Patel Hiren V, Srivastava Arnav, Singer Eric A
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Cancers (Basel). 2021 Aug 17;13(16):4140. doi: 10.3390/cancers13164140.
Patients with advanced or malignant renal cell carcinoma at the time of diagnosis have historically had a poor prognosis. Immunonologic agents have significantly altered the therapeutic landscape and clinical outcomes of these patients. In this review, we highlight recent and upcoming clinical trials investigating the role of immunotherapies in clear cell RCC. In particular, we emphasize immunotherapy-based combinations, including immune checkpoint inhibitor (ICI) combinations, neoadjuvant, and adjuvant ICI, and ICI agents combined with anti-VEGF therapy.
在诊断时患有晚期或恶性肾细胞癌的患者，历来预后较差。免疫治疗药物显著改变了这些患者的治疗格局和临床结局。在本综述中，我们重点介绍了近期及即将开展的关于免疫疗法在透明细胞肾细胞癌中作用的临床试验。特别是，我们强调基于免疫疗法的联合治疗，包括免疫检查点抑制剂（ICI）联合治疗、新辅助和辅助ICI治疗，以及ICI药物与抗血管内皮生长因子（VEGF）治疗联合应用。
